Introduction
Paroxib IM/IV Injection 40 mg/vial is a water-soluble and injectable prodrug of valdecoxib. Paroxib IM/IV Injection 40 mg/vial is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications.
Uses
Paroxib IM/IV Injection 40 mg/vial is a selective COX-2 inhibitor and NSAID used for the short-term management of perioperative pain.
Used for short term perioperative pain control.
Associated Conditions
Protein Binding
98%
Half Life
22 minutes (parecoxib); 8 hours (valdecoxib)
Food Interactions
No interactions found.
Dosage
Adult: The recommended dose is 40 mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg/day. As the cardiovascular risk of COX-2 specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. There is limited clinical experience with Paroxib IM/IV Injection 40 mg/vial treatment beyond three days.
Elderly: No dose adjustment is generally necessary in elderly patients (≥65 years). However, for elderly patients weighing less than 50 kg, treatment should be initiated with half the usual recommended dose of Paroxib IM/IV Injection 40 mg/vial and reduce the maximum daily dose to 40 mg.
Children: The safety and efficacy of parecoxib in children under 18 years old have not been established. No data are available. Therefore, parecoxib is not recommended in these patients.
Elderly: No dose adjustment is generally necessary in elderly patients (≥65 years). However, for elderly patients weighing less than 50 kg, treatment should be initiated with half the usual recommended dose of Paroxib IM/IV Injection 40 mg/vial and reduce the maximum daily dose to 40 mg.
Children: The safety and efficacy of parecoxib in children under 18 years old have not been established. No data are available. Therefore, parecoxib is not recommended in these patients.
